Biosite and Phase 2 link up on brain injury test
This article was originally published in Clinica
Executive Summary
Biosite is to assess the use of a biomarker called C-tau in diagnostic tests for stroke and brain injury, after licensing the marker from private US firm Phase 2 Discovery.